Please login to the form below

Not currently logged in
Email:
Password:

daclatasvir

This page shows the latest daclatasvir news and features for those working in and with pharma, biotech and healthcare.

Gilead gets OK for three-in-one hep C therapy in US

Gilead gets OK for three-in-one hep C therapy in US

Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.

Latest news

More from news
Approximately 7 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics